Everest Organics launches Posaconazole for Black Fungus treatment

Everest Organics Limited said that it has developed and launched Posaconazole, an anti-fungal API for the treatment of black fungus associated with Covid-19 patients.

Posaconazole is a triazole antifungal agent indicated for treating mucormycosis (or Black Fungus) which has become prevalent in several Covid patients during the second wave in India.

Everest Organics launches Posaconazole for Black Fungus treatment in Covid-19 patients
Everest Organics launches Posaconazole for Black Fungus treatment in Covid-19 patients. Image courtesy of Pete Linforth from Pixabay.

Dr. Srikakarlapudi Sirisha – Director of Everest Organics said: “The Everest Organics Limited has successfully developed the API Posaconazole using its own in-house R&D strength at lab scale in short span of time. Further we are in advance stage of commercializing the same. Everest has successfully in near past launched and commercialized ‘Oseltamivir’ and ‘Remdesivir‘ both being used for Covid-19.

“Now we are more confident and are poised for development of more niche products in the quickest span of time because of our R&D strength.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Mérieux NutriSciences expands global food safety operations with Bureau Veritas acquisition
Total
0
Shares
Related Posts
Read More

Aptorum to develop drugs for treatment of obesity and neuroblastoma

Aptorum Group said that it will undertake the development of CLS-1 microbiome drug candidate and certain repurposed drug candidates for the treatment of obesity and neuroblastoma, respectively. Based in Hong Kong, Aptorum Group is a pharma company focused on the development of new drugs to treat unmet medical needs. The company said that its wholly-owned subsidiary […]

The post Aptorum to develop drugs for treatment of obesity and neuroblastoma appeared first on PharmaNewsDaily.com.